Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeut

Go online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-B

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, a

Go online to PeerView.com/NYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in fibrodysplasia ossificans progressiva (FOP) discuss the pathophysiology, prevalence, and burden of the disease, as well as the disease’s manifestations and common misdiagnoses. With a focus on improving patient care and quality of life, the activity also includes a patient interview and 3D animation and is part of a larger education collection on FOP. Upon completion of this activity, participants should be better able to: Describe the mechanism of disease of FOP, including the underlying genetic pathophysiology; Summarize the spectrum of FOP disease manifestations, understanding the holistic burden on the patient and impact on quality of life; and Avoid iatrogenic harm caused by diagnostic errors by correctly identifying patients with the clinical hallmarks of FOP

Go online to PeerView.com/SFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new PeerView activity based on a recorded symposium at the 75th Annual Bleeding Disorders Conference, an expert panel engages in thought-provoking, interactive case-based discussions and offers guidance on how healthcare professionals can address real-world challenges of hemophilia A management with novel EHL FVIII prophylaxis. Our experts provide guidance on critically evaluating the latest clinical evidence, tailoring treatment plans to individual patient needs, and navigating the challenges associated with patient adherence, access to therapy, and transitioning patients from conventional options (eg, SHL FVIII replacement therapy) to innovative EHL FVIII prophylaxis. Access this activity now to see if you are prepared to lead the way to better outcomes for hemophilia A! Upon completion of this activity, participants should be better able to: Summarize the mechanistic

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable

Go online to PeerView.com/UTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care. Upon completi

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, particip

Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors; Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs; and Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are releva

Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and B

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don’t miss this opportunity to see how your team can take command of care when ma

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is

Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impac

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants sh

Go online to PeerView.com/AYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging and animated activity, an expert on EGFR exon 20 insertion–positive NSCLC discusses the role of biomarker testing and examines the evidence for new and emerging therapies to offer patient-centered guidance on individualizing care and improving outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of EGFR mutations in NSCLC, frequency and characteristics of EGFR exon 20 insertion mutations, latest evidence and guidelines on targeted therapies in this setting, and importance of biomarker testing to identify patients for these therapies in clinical practice; Apply multidisciplinary strategies for biomarker testing and targeted treatment selection and sequencing to optimize therapeutic outcomes in patients with NSCLC harboring EGFR exon 20 insertion mutations; and Engage patients with EGFR exon 20 insertion–posi

Go online to PeerView.com/WEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you aware of the evidence supporting the use of innovative EHL FVIII therapies for the prophylactic management of hemophilia A? Find out in this activity based on a “MasterClass” event recorded at the 2023 Congress of the International Society on Thrombosis and Haemostasis. Hear what hemophilia experts are saying about the latest clinical evidence that supports the use of innovative EHL FVIII therapy in hemophilia as they link the data directly to case-based decisions in real-world settings—with a goal of clearly illustrating the practicalities of safely using novel and emerging factor products. The experts also provide guidance on implementing evidence-based protocols and preventing and managing complications in the context of EHL FVIII therapy. Upon completion of this activity, participants should be better able to: Assess the latest safety, efficacy, and pharmacokinetic d

Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent

Go online to PeerView.com/PYA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Newer treatment modalities for acute myeloid leukemia (AML) have rapidly eclipsed the decades-long cytarabine-based standard of care and helped clinicians adopt more personalized management using innovative cytotoxic platforms, targeted agents (including FLT3, BCL2, and IDH inhibitors), and other unique management strategies. Clinicians can now improve patient outcomes across all AML treatment settings, while at the same time selecting the most potent, personalized option that can be designed to address a given patient’s needs. This “Seminars and Tumor Board” activity, adapted from our recent live event held at the 2023 ASCO Annual Meeting and developed in collaboration with the HealthTree Foundation for Acute Myeloid Leukemia, reveals how modern baseline assessment paired with cutting-edge prognostication has pushed patient management to new heights of innovation and changed th